Skip to main content
. 2018 Apr 20;42(1):141–148. doi: 10.3892/ijmm.2018.3637

Figure 6.

Figure 6

miR-222 inhibitor promotes the expression of BBC3 in HepG2 cells. (A) Compared with that in HepG2 cells in the control and miR-NC inhibitor groups, miR-222 inhibitor significantly increased the immunofluorescence intensity of BBC3 (magnification, ×400). (B) Western blot analysis indicated that compared with HepG2 cells in the control and miR-NC inhibitor groups, miR-222 inhibitor decreased Bcl-2 and cyclin D1 protein levels, increased the protein levels of BBC3 and cleaved caspase-3 in HepG2 cells. (C–F) The corresponding statistical data of BBC3, cyclin D1, Bcl-2, and cleaved caspase-3 were exhibited. Bcl-2, B-cell lymphoma 2; miR, microRNA; NC, negative control; Con, control; BBC3, Bcl-2 binding component 3. **P<0.01 miR222 inhibitor group vs. NC group.